506390 TumorGenesis® Primary Ovarian Cancer Maintenance Media (Ince OCMI-L) (Liquid)

$579.00

Primary Ovarian Cancer Maintenance Media (Ince).

Use OCMI-L medium for established OCI lines only.

Suggested Usage

PRIMARY HUMAN OVARIAN CARICINOMA CELL LINES OCI-C1p Clear Cell Primary OCI-C4p Clear Cell Primary OCI-C5x Clear Cell Xenograft OCI-P2a Serous Ascites OCI-P5x Serous Xenograft OCI-P7a Serous Ascites OCI-P8p Serous Primary OCI-P9a1 Serous Ascites FCI-P2p Serous Primary OCI-CSp Carcinosacroma

Tan A. Ince, MD, PhD – Fighting Cancer by Keeping Cancer Cells Alive … https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/

Feb 12, 2017 – Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.

Clear
SKU: 506390 Category:

Customer supplied
To be supplemented with 5% fetal bovine serum to media To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Appearance
Red, clear, complete

OCMI-L Bullet 1 Included (506390B, Colorless)
Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506390.

Storage (506390B)
Liquid is stable at 4°C.

OCMI-L Bullet 2 Included (506390C, Pink)
Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506390.

Storage (506390C)
Liquid is stable at -20°C.

(w/o supplements)
Storage and Stability Store at 4°C. Do not freeze. Stable for 6 months w/o supplements. Light sensitive, store in the dark.

(w/ supplements)
Storage and Stability Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.

Country of Origin
United States

Important Note
Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Licensed by TumorGenesis. Manufactured for research use by US Biological.

1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive. 2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337. 3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90. 4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419. 5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.